indomethacin Side Effects
Also known as: Indocin
Analysis of 12,919 adverse event reports submitted to the FDA from 1994 to 2025.
Total Reports
12,919
Death-Related
1,495
11.6% of reports
Hospitalizations
4,370
33.8% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 1,495 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DYSPNOEA | 315 |
| DIARRHOEA | 296 |
| DIZZINESS | 281 |
| ARTHRALGIA | 279 |
| ASTHENIA | 272 |
| SEPSIS | 270 |
| PRURITUS | 268 |
| FATIGUE | 262 |
| INSOMNIA | 262 |
| CARDIO-RESPIRATORY ARREST | 255 |
| PYREXIA | 254 |
| HEADACHE | 252 |
| DECREASED APPETITE | 251 |
| HAEMORRHAGIC STROKE | 242 |
| FALL | 239 |
| DEATH | 237 |
| TACHYCARDIA | 236 |
| COUGH | 221 |
| ALTERED STATE OF CONSCIOUSNESS | 220 |
| ABDOMINAL PAIN | 217 |
Reactions in Hospitalization Reports
Top reactions in 4,370 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| PAIN | 346 |
| DYSPNOEA | 322 |
| DRUG INEFFECTIVE | 315 |
| ARTHRALGIA | 297 |
| PYREXIA | 293 |
| DIARRHOEA | 290 |
| FATIGUE | 290 |
| HEADACHE | 267 |
| DIZZINESS | 263 |
| VOMITING | 262 |
| NAUSEA | 255 |
| ASTHENIA | 254 |
| OFF LABEL USE | 251 |
| HYPERTENSION | 223 |
| PAIN IN EXTREMITY | 216 |
| CONDITION AGGRAVATED | 213 |
| PNEUMONIA | 209 |
| FALL | 206 |
| RENAL FAILURE | 203 |
| CHEST PAIN | 198 |
Nearby — Related Medications
What the FAERS Data Reveals About indomethacin Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 12,919 voluntary reports linked to indomethacin and its brand equivalents (Indocin), spanning 1994 through 2025. Of those, 1,495 (11.6%) listed death as an outcome and 4,370 (33.8%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 52% were female and 47% male; age distribution skews toward 45-64, with 3,260 reports in that bracket. The single most reported reaction is drug ineffective with 1,371 submissions, followed by fatigue and arthralgia.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.